Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

125.87 +0.87 (+0.70%)
Streaming Delayed Price Updated: 10:34 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Bioscienc

< Previous 1 2 3 4 5 6 7 8 9 Next >
NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024
NBIX stock results show that Neurocrine Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win
The company makes Ingrezza, a treatment for the movement disorder known as tardive dyskinesia. 
Via Investor's Business Daily
Sarepta Therapeutics Stock Shows Improved Technical Strength
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. 
Via Investor's Business Daily
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
Why NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill
Where Neurocrine Biosciences Stands With Analysts
Via Benzinga
NASDAQ:NBIX is not too expensive for the growth it is showing.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is showing decent growth, but is still valued reasonably. 
Via Chartmill
3 Red-Hot Biotech Rockets Blasting Off in 2024
The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits. 
Via InvestorPlace
Topics Economy
Exposures Economy
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in... 
Via Benzinga
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza. 
Via Investor's Business Daily
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
From Sentia Medical Sciences, Inc.
Via GlobeNewswire
The 5 Stocks Most Sold By Insiders This Year
Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices. 
Via MarketBeat
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Why Quality-Oriented Investors Should Consider NASDAQ:NBIX.
Analyzing the Quality Characteristics of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. 
Via Chartmill
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.
In a market where value is scarce, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind
DexCom, Blackstone and Royal Caribbean head this list of five stocks. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term... 
Via Benzinga
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
Decoding 8 Analyst Evaluations For Neurocrine Biosciences
Via Benzinga
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock?
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base
Three of the featured stocks are closing in on record highs. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
NASDAQ:NBIX is probably undervalued for the fundamentals it is displaying.
When you look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences
Via Benzinga
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector. 
Via InvestorPlace
Amicus Therapeutics Stock Sees RS Rating Improve To 74
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced.
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. 
Via Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. 
Via Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84. 
Via Investor's Business Daily
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.